Cisplatin treatment for oropharyngeal cancer

Author: ukct

August undefined, 2024

WebWe found no significant differences in survival or grade ≥ 3 side effects comparing simultaneous integrated boost and brachytherapy boost as alternative dose escalation modalities in the treatment of oropharyngeal cancer. Supplementary Information The online version contains supplementary material available at 10.1186/s13014-023-02256-x. WebNov 15, 2024 · Cisplatin chemotherapy can bring lasting adverse health effects, but a new, presumably less-toxic alternative is not as effective at promoting survival, according to a large, Stanford-led trial. Traditional …

Dose escalation in oropharyngeal cancer: a comparison of …

WebCisplatin is the standard cytotoxic agent that has been used ... Mady LJ, Baddour K, Hodges JC, et al. The impact of frailty on mortality in non-surgical head and neck cancer treatment: shifting the clinical paradigm. ... Egerman MA, Bui AH, et al. A new face of the HPV epidemic: oropharyngeal cancer in the elderly. Oral Oncol. 2024;109:104687 ... WebSep 18, 2024 · NCBI Bookshelf the purpose of openstack horizon is to

Surgery Vs Chemoradiation for Oropharyngeal Cancer- A …

WebMar 23, 2024 · The chemo drugs used most often for cancers of the oral cavity and oropharynx that can be given with or without radiation include: Cisplatin Carboplatin 5-fluorouracil (5-FU) Paclitaxel (Taxol) Docetaxel (Taxotere) Hydroxyurea Other drugs that are used less often include: Methotrexate Capecitabine WebOct 22, 2024 · This study shows that the best treatment choice for patients with HPV-positive throat cancer is cisplatin and radiotherapy. This combination gives ‘double’ the benefit since it is more effective in terms of survival and does not worsen all grade toxicity compared to cetuximab with radiotherapy.” http://www.nrgoncology.org/Home/News/Post/treatment-de-intensification-for-early-stage-hpv-positive-oropharyngeal-cancer-nrg-hn005 the purpose of open ended questions

Reduced-Dose Radiation with Cisplatin Improves Outcomes f

Evaluation of sarcopenia as a prognostic biomarker in locally …

WebApr 12, 2024 · The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: the prospective PLATISMA study. Eur. J. Cancer 160, 92–99 (2024). •• Pivotal study investigating the mechanism of cisplatin toxicity in sarcopenia.Crossref, Medline, CAS, Google Scholar; 46. Lutz CT, Quinn LS. WebFeb 21, 2024 · Although de-intensification strategies have been propelled to the forefront of clinical research in human papillomavirus (HPV) positive oropharyngeal cancer, three … the purpose of organisingWebJan 7, 2024 · Cisplatin treatment was administered as a triweekly regimen, which differs from this study where weekly, low-dose treatment was used. There was a significantly … sign in accounts

"WebOct 22, 2024 · This study shows that the best treatment choice for patients with HPV-positive throat cancer is cisplatin and radiotherapy. This combination gives ‘double’ the … " - Cisplatin treatment for oropharyngeal cancer

Cisplatin treatment for oropharyngeal cancer

Radiotherapy plus cisplatin or cetuximab in low-risk human ...

WebFeb 16, 2024 · What is cisplatin? Cisplatin is used together with other cancer drugs to treat bladder cancer, testicular cancer, or ovarian cancer. Cisplatin may also be used … WebSep 15, 2024 · Aluminum reacts with cisplatin (cisplatin injection) , causing precipitate formation and a loss of potency. Metastatic Testicular Tumors - The usual cisplatin …

Did you know?

WebApr 15, 2024 · The trial will directly compare clinical outcomes related to de-intensification strategies in HPV-positive oropharyngeal disease through use of both reduced intensity radiation and/or nivolumab therapy. Similar to NRG-HN004 in cisplatin-ineligible patients, immune checkpoint therapy is added to augment RT-induced immunogenic cell death … WebOct 1, 2024 · Cetuximab represents a potential option for those ineligible for cisplatin or, until recently, an agent for de-escalation in low risk HPV+ oropharyngeal carcinoma (OPSCC). Our objective was to...

WebMay 20, 2024 · The current treatment landscape for oropharyngeal cancer At one time, traditional open surgery was a common treatment for oropharyngeal cancer, often … WebNov 11, 2024 · Performance status, higher N stage, HPV status, and use of cisplatin were associated with better PFS on univariable analysis (eTable 3 in the Supplement). On multivariable analysis, only KPS (HR, 0.90; ... and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer. Radiother Oncol. 2024;147:64-74. doi: ...

WebJun 6, 2024 · Results of our study show that, in the setting of low-risk oropharyngeal squamous cell carcinoma, the use of cetuximab bioradiotherapy instead of cisplatin-based chemoradiotherapy resulted in no overall benefit in terms of toxicity but showed significant detriment in tumour control. WebNov 9, 2024 · INTRODUCTION Human papillomavirus (HPV) infection, a common sexually transmitted disease, has been associated with the development of many cancers, including oropharyngeal squamous cell carcinoma (OPSCC) of the head and neck. (See "Virology of human papillomavirus infections and the link to cancer" .) While traditional, …

WebMay 6, 2024 · The standard treatment of early-stage HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) includes one or a combination of surgery, radiation, …

WebFeb 2, 2024 · The benefit of adding concomitant high-dose cisplatin to adjuvant radiotherapy (RT) for resected head and neck squamous cell carcinoma (HNSCC) was established in two large seminal trials, EORTC 22931 and RTOG 9501. 1 - 3 In these studies, cisplatin was administered at a dose of 100 mg/m 2 on days 1, 22, and 43 … sign in account.live.comWebOropharyngeal Cancer—Lessons Learnt from Recent Trials Hisham Mehanna Introduction Human papillomavirus (HPV)—mediated oropharyngeal cancer (OPC) has been ... it is … sign in accounts google classroomWebMay 27, 2024 · The majority of newly diagnosed oropharyngeal squamous cell carcinoma (OPSCC) is associated with human papillomavirus (HPV) infection, portending very good … sign in account microsoftWebThe treatment of locally advanced head and neck cancer (HNC) is based on extensive resections followed by concurrent chemoradiotherapy (CRT) with platinum derivatives or concurrent radiotherapy with cetuximab (bioradiotherapy; BRT). Malnutrition, which occurs in up to 60% of patients before treatment commencement, severely increases the risk of … sign in account samsung.comWebTreatment for oropharyngeal cancer may include: Surgery Radiotherapy Chemotherapy Chemoradiation Immunotherapies You may have some treatments as part of a clinical trial. After oropharyngeal cancer treatment You have regular follow-up appointments after treatment with your specialist doctor. These may continue for several years. sign in accounts windows 11WebJan 29, 2024 · A combination of reduced-dose radiotherapy using intensity-modulated radiotherapy (IMRT) combined with concurrent cisplatin met the threshold for disease … sign in acellusWebApr 7, 2024 · Local recurrence is the most common pattern of failure in head and neck cancer. It can therefore be hypothesised that some of these patients would benefit from an intensified local treatment, such as radiation dose escalation of the primary tumour. This study compares treatment and toxicity outcomes from two different boost modalities in … sign in accounts windows